Skip to main content
Pharmafile

Is the Current EU Legal Framework for Orphan Medicines Fit for Purpose?

Autumn 2019
Authors
Maria Isabel ManleyDr. Chris Boyle

Maria Isabel Manley, partner and head of the UK Global Life Sciences Practice, and Chris Boyle, associate, at Sidley, discuss the impact of regulatory frameworks on medicines for rare diseases.

View Article

Contacts

Manley, Maria Isabel
Partner
Boyle, Chris
Partner

Capabilities

Suggested News & Insights

Sidley Represents Changchun GeneScience (GenSci) Pharmaceuticals in Its Strategic Licensing Agreement With Yarrow Bioscience for First-in-Class Autoimmune Thyroid Disease TherapyDecember 18, 2025
Announcements
Sidley Represents Immunovant in US$550 Million OfferingDecember 12, 2025
Announcements
BIOSECURE Act Included in the FY2026 National Defense Authorization ActDecember 12, 2025
Government Strategies Update
What the U.S.–UK Drug Pricing Agreement Reveals About How MFN Drug Policy Could Impact the UK and EUDecember 10, 2025
Global Life Sciences Update
U.S. FDA's Adoption of ICH E6(R3) Good Clinical Practice: Key Takeaways for Sponsors and InvestigatorsDecember 4, 2025
Global Life Sciences Update
Sidley Represents PayRange in Its Acquisition of KioSoftDecember 1, 2025
Announcements